Hospital La Milagrosa S.A.

Madrid 27 trials 14 recruiting

27 Registered trials

14 Currently recruiting

Organisation

Hospital La Milagrosa S.A.

Location

Madrid, Spain

Identifier

ORG-100046630

Address

Calle Modesto Lafuente 14, 28010, Spain

Departments

#1117
#3459: Cardiología
Cardiology department
Consultas Externas
Epilepsy
Epilepsy Program, Vithas Neuroscience Institute
Epilepsy Unit
Medical oncologist
Neurology
Neurophysiology
Oncología
Oncology
Pneumology service
Servicio de Reumatología
Thoracic Oncology

Clinical trials at this site (27)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Pending

2025-523911-13-00 Narcolepsy Type 1 5
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting

2025-522896-27-00 Asthma 4 2026-05-11
A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting

2024-514974-39-00 Developmental and Epileptic Encephalopathies (DEEs) 5 2025-10-10
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Refractory Partial Onset Epilepsy 5 2025-03-12
A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer Recruiting

2024-514048-98-00 Previously Untreated Metastatic Non-Squamous Non-Small 5 2025-01-30
A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting

2022-502286-16-00 Primary Generalized Tonic-Clonic Seizures 5 2023-10-27
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy. Recruiting

2025-521640-38-00 Focal onset seizures or primary generalized tonic-cloni 5 2025-10-16
A Phase 3, placebo-controlled study to investigate LP352 in children and adults with Developmental and Epileptic Encephalopathies Recruiting

2024-516412-17-00 Developmental and Epileptic Encephalopathies (DEE) 5 2025-08-26
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Recruiting

2024-514937-39-00 Dravet Syndrome 5 2025-05-20
Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting

2024-513959-33-00 Asthma 4 2025-05-13
A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas… Recruiting

2023-508112-35-00 ROS1-positive non-small cell lung cancer (NSCLC) with a 4 2025-04-15
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Multicenter, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy and safety of donepezil versus placebo i… Recruiting

2024-510959-35-00 Parkinson's disease 4 2023-09-07
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA) Recruiting

2024-512701-11-00 Systemic Juvenile Idiopathic Arthritis (sJIA) 4 2018-08-29
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi… Ended

2023-506301-20-00 Tuberous Sclerosis Complex (TSC) 9 2024-04-15
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 Deficiency Disorder Ended

2023-506269-78-00 CDKL5 Deficiency disorder 5 2023-06-20
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic… Ended

2024-517061-16-01 Focal onset seizures or primary generalized tonic-cloni 4 2025-02-27
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended

2024-514559-13-00 Focal Epilepsy 10 2024-11-26
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release… Ended

2023-505296-72-00 Idiopathic Pulmonary Fibrosis (IPF) 4 2023-12-12